We have located links that may give you full text access.
Platypnea-Orthodeoxia: A Case of Unexplained Hypoxia.
INTRODUCTION: Platypnea-orthodeoxia syndrome is a rare clinical syndrome defined by worsening deoxygenation and dyspnea when changing to an upright sitting or standing position. It is seen in 3 different clinical scenarios: intracardiac shunts, pulmonary arteriovenous shunts, and ventilation/perfusion mismatch in the lungs.
CASE: An 82-year-old woman with a history of nonischemic cardiomyopathy with reduced ejection fraction was admitted with dyspnea and hypoxemia. She was found to have atrial septal defect with right to left shunting in the setting of normal right atrial pressures.
DISCUSSION: Platypnea-orthodeoxia syndrome is a clinical syndrome where, in the setting of an interatrial communication, a right to left shunt can occur without elevated pulmonary or right atrial pressure, resulting in significant hypoxia.
CONCLUSION: Platypnea-orthodeoxia syndrome is a clinical condition that is being recognized more frequently due to more accurate diagnosis, and its treatment can alleviate symptomatic hypoxemia.
CASE: An 82-year-old woman with a history of nonischemic cardiomyopathy with reduced ejection fraction was admitted with dyspnea and hypoxemia. She was found to have atrial septal defect with right to left shunting in the setting of normal right atrial pressures.
DISCUSSION: Platypnea-orthodeoxia syndrome is a clinical syndrome where, in the setting of an interatrial communication, a right to left shunt can occur without elevated pulmonary or right atrial pressure, resulting in significant hypoxia.
CONCLUSION: Platypnea-orthodeoxia syndrome is a clinical condition that is being recognized more frequently due to more accurate diagnosis, and its treatment can alleviate symptomatic hypoxemia.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app